Tocagen (TOCA) Earns Daily Media Impact Rating of 0.02

Headlines about Tocagen (NASDAQ:TOCA) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tocagen earned a media sentiment score of 0.02 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.1866270888357 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Separately, Zacks Investment Research downgraded shares of Tocagen from a “hold” rating to a “sell” rating in a research report on Tuesday, August 15th.

Tocagen (TOCA) traded up $0.16 during mid-day trading on Friday, reaching $10.78. 112,532 shares of the company’s stock traded hands, compared to its average volume of 150,403. The company has a quick ratio of 6.03, a current ratio of 6.03 and a debt-to-equity ratio of 0.07. Tocagen has a 12 month low of $8.60 and a 12 month high of $17.95.

Tocagen (NASDAQ:TOCA) last posted its earnings results on Wednesday, November 8th. The company reported ($0.50) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.02). The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million. equities research analysts predict that Tocagen will post -2.88 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Week Herald and is owned by of Week Herald. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at

Tocagen Company Profile

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Insider Buying and Selling by Quarter for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with's FREE daily email newsletter.

Leave a Reply